Prospective clinical trial of gelatin‐thrombin matrix as first line treatment of posterior epistaxis

Abstract

This pilot study demonstrated that gelatin-thrombin matrix is a safe and both a clinically effective and cost-saving means of treating posterior epistaxis. In this study, its use is associated with a low level of discomfort. This treatment method may improve the quality of care for patients with posterior epistaxis.